11 results
To determine the proportion of successful alignment after treatment of infantile esotropia with Botox.
1. We want to study the success rate of OAHM withdrawal in patients with chronic migraine related to support by a headache nurse, and onabotulinum toxin A injections during the withdrawal period, and the influence of comorbid depression.2. We want…
- Can early Botox-injections in the bladder of patients with meningomyelocèle (MMC) prevent deterioration of the bladder and renal function?- Can early Botox-injections in the bladder of patients with meningomyelocèle (MMC) decrease the need for an…
To evaluate the efficacy and safety of BOTOX® 100 U compared with placebo in patientswith idiopathic OAB with urinary incontinence whose symptoms have not been adequatelymanaged with anticholinergic therapy.
Objective: The principal objective is To evaluate the long-term safety and maintenance of efficacy of BOTOX® (200 U) injected into the detrusor for the treatment of urinary incontinence caused by neurogenic detrusor overactivity in patients who have…
To determine the effect on lower urinary tract symptoms and to determine urodynamic and histologic changes after intraprostatic botulinum toxin type A injection.
To assess the efficacy of the co-administration of lanreotide Autogel 120 mg(administered via deep sub-cutaneous injections every 28 days) and pegvisomant(administered at 40 to 120 mg per week via sub-cutaneous injection given once ortwice a week)…
Objective: The principal objective is to evaluate the safety and efficacy of two doses of BOTOX (200 Units or 300 Units) compared with placebo injected into the bladder wall in patients who have urinary incontinence due to neurogenic detrusor…
To evaluate the responsiveness of the extensor digitorum brevis (EDB) muscle to BoNT/A in extremities affected and unaffected by CRPS.
The objective of this study is to investigate whether BTA injection in the pelvic floor muscle is an effective treatment for patients with chronic pelvic pain and pelvic floor hypertonicity.
To assess the anti-tumor activity of LGX818/MEK162 in combination with third targeted agents after progression on LGX818/MEK162 combination therapy.